---
title: "EASTON BIOPHARMACEUTICALS: The hydrochloride of Nafamostat mesylate orally disintegrating tablets has obtained a drug registration certificate"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/255438066.md"
description: "EASTON BIOPHARMACEUTICALS recently obtained the drug registration certificate for hydrochloride nafurafine orally disintegrating tablets approved by the National Medical Products Administration. This drug is mainly used to improve pruritus in patients undergoing hemodialysis. Hydrochloride nafurafine is classified as a Class II psychotropic drug, and its approval is considered equivalent to passing the consistency evaluation. The product meets the drug registration requirements and is expected not to have a significant impact on the company's recent performance"
datetime: "2025-09-01T09:23:03.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/255438066.md)
  - [en](https://longbridge.com/en/news/255438066.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/255438066.md)
generator: "portal-rs"
---

# EASTON BIOPHARMACEUTICALS: The hydrochloride of Nafamostat mesylate orally disintegrating tablets has obtained a drug registration certificate

According to the Zhitong Finance APP, EASTON BIOPHARMACEUTICALS (688513.SH) announced that it recently received the drug registration certificate for buprenorphine hydrochloride orally disintegrating tablets approved and issued by the National Medical Products Administration (referred to as "NMPA"). The main active ingredient of buprenorphine hydrochloride orally disintegrating tablets is buprenorphine hydrochloride, which is classified as a Class II psychotropic drug according to the National Regulations on the Administration of Narcotic Drugs and Psychotropic Substances. The indication is for the improvement of pruritus in patients undergoing hemodialysis (limited to cases where existing treatment is not effective).

The company's buprenorphine hydrochloride orally disintegrating tablets are registered and declared as Class 4 chemical drugs, and approval is considered equivalent to passing the consistency evaluation. The approval of this drug indicates that the product meets the relevant requirements for drug registration and will not have a significant impact on the company's recent performance

### Related Stocks

- [688513.CN](https://longbridge.com/en/quote/688513.CN.md)

## Related News & Research

- [Promise Analyzes Telehealth Licensing Rules as Compact Hits Record 3,633 Licenses in a Month](https://longbridge.com/en/news/296635882.md)
- [HENGRUI PHARMA  1H26 Net Profit Rises 0.3% YoY to RMB4.465 Billion; Shares Now Down Over 7%](https://longbridge.com/en/news/296422700.md)
- [US health agencies report 55 cases of E. coli and salmonella infections tied to alfalfa sprouts](https://longbridge.com/en/news/296645342.md)
- [FOCUS-Green giant: How Taylor Farms became a top salad supplier before US diarrhea outbreak](https://longbridge.com/en/news/296469939.md)
- [Desert Control issued shares rise to 407,935,164 after capital increase registration](https://longbridge.com/en/news/296688306.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**